Press release
Growth Dynamics on Orphan Drugs Market 2019-2025| Key Players: Bayer AG, Hoffmann-La Roche Ltd., Alexion Pharmaceuticals Inc., Novo Nordisk A/S & more
Sample PDF Brochure:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/orphan-drugs-market-100088
Some of the Main Key Players Covered in the Report:
• Bayer AG
• Hoffmann-La Roche Ltd.
• Alexion Pharmaceuticals Inc.
• Novo Nordisk A/S
• Novartis AG
• Bristol-Myers Squibb Company
• AstraZeneca plc.
• Daiichi Sankyo Company Limited
• GlaxoSmithKline plc.
• Amgen Inc.
North America is expected to remain dominant in the Global Orphan Drugs Market between 2018 and 2025. This information was found by Fortune Business Insights in a report, titled “Orphan Drugs Market: Global Market Analysis, Insights and Forecast, 2018-2025”. According to the report, the global orphan drugs market was valued at US$ 125000 Mn in 2017 and is anticipated to reach US$ 294000 Mn by 2025. The report also stated that the market will exhibit a remarkable CAGR of 11.4% during the forecast period
This is further helping the orphan drugs market to grow impressively in this region. Asia Pacific, on the other hand, is anticipated to show a higher rate of growth on account of rising prevalence of rare diseases such as chronic lymphocytic leukemia. Also, the region is expected to offer lucrative growth opportunities as a result of the rapid expansion of healthcare infrastructure.
Rising Prevalence of Cancer and Related Diseases Fuels Demand for Orphan Drugs
The oncology segment is witnessing considerably high demand on account of the rising number of patients suffering from different types of cancers. This also increases the demand for novel therapeutics, which as per the report will bode well for the global orphan drugs market. According to the National Center for Health Statistics, the U.S. is likely to witness around 1,762,450 new cancer cases in 2019.
Spurred by these numbers, the demand for orphan drugs is likely to increase in the coming years. Governments are investing heavily to build a strong framework for supporting drug development, thus offering a significant impetus to the orphan drugs market. Furthermore, the return on investment, with regards to orphan drugs, is expected to be higher than non-orphan drugs, which in turn is increasing the demand for orphan drug therapeutics worldwide.
“People across the world are becoming more aware about the rising prevalence of rare disorders and importance of orphan drugs,” stated a lead analyst at Fortune Business insights. “This, coupled with robust support from EU and FDA to drug development, drives the orphan drugs market,” he added. Several pharma companies are also putting continuous efforts to develop orphan drugs, thus improving creating scope for generating more revenue in the overall global market for orphan drugs.
Treatment and Medications Associated with Rare Diseases Are Expensive, Limiting Growth of Orphan Drugs Market
Although the orphan drugs market is growing at a good pace, there are some factors that may hinder its growth. High cost of orphan drugs, insufficient information on rare diseases, and lack of skilled healthcare professionals are factors restricting growth in the global orphan drugs market. In addition to this, rising competition from generic industries may pose a serious threat to the growth of the market.
Emergence of New Players to Drive the Orphan Drug Market and Increase Competition
The global orphan drugs market is anticipated to pave way for the entry of several new players in the coming years. This is mainly because of the rapid drug development and discovery over the years. Several leading companies are manufacturing orphan drugs to build a nimble and agile framework. Some of the savvy players present in the global orphan drugs market are Actelion Pharmaceuticals Ltd., Biogen, Eli Lilly and Company, Bayer AG, Amgen Inc., and Pfizer Inc. These leading players are likely to give tough competition to the small entrants. Therefore, these small scale companies may need support from governments and other authorities to sustain in the market.
Browse Complete Report Details:
https://www.fortunebusinessinsights.com/industry-reports/orphan-drugs-market-100088
About us:
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities
Contact Us:
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Growth Dynamics on Orphan Drugs Market 2019-2025| Key Players: Bayer AG, Hoffmann-La Roche Ltd., Alexion Pharmaceuticals Inc., Novo Nordisk A/S & more here
News-ID: 1780278 • Views: …
More Releases from Fortune Business Insights
Future of Renewable Energy Market Insights: Growth Drivers, and Regional Develop …
Global Renewable Energy Market Overview
The global renewable energy market size was valued at USD 954 billion in 2023. The market is projected to grow from USD 1,020.94 billion in 2024 to USD 1,574.17 billion by 2032, exhibiting a CAGR of 5.56% during the forecast period. Asia Pacific dominated the renewable energy market with a market share of 67.76% in 2023. The Renewable energy market in the U.S. is projected to…
DC Drives Market Overview: Opportunities, Growth Drivers, and Key Applications
Market Overview
The global DC drives market size was valued at USD 4.34 billion in 2018 and is projected to reach USD 9.23 billion by 2032, exhibiting a CAGR of 5.59% during the forecast period of 2019-2032. Asia Pacific dominated the global market with a share of 28.8% in 2018. The DC drives market in the U.S. is projected to grow significantly, reaching an estimated value of USD 1.59 billion by…
Humanoid Robots Market: An In-depth B2B Analysis of Size, Share, and Future Grow …
Brief Market Overview:
The global humanoid robots market is rapidly transitioning from a nascent field into a major growth sector, with its value escalating from USD 2.43 billion in 2023 to a projected USD 66.0 billion by 2032, demonstrating a remarkable CAGR of 45.5%.
These complex machines, which merge mechanical, electrical, and software engineering, are moving beyond research labs into real-world applications across industrial, service, and household sectors. This explosive growth…
Methanol Market Poised for Remarkable Growth, set to Reach USD 46.32 billion by …
The global methanol market size was valued at USD 31.26 billion in 2023. It is projected to grow from USD 32.70 billion in 2024 to USD 46.32 billion by 2032, exhibiting a CAGR of 4.5% during the forecast period.
The global methanol market size is set to gain traction from the urgent need to lower environmental pollution caused by the surging usage of heavy fuels, such as diesel and gasoline. Pollution…
More Releases for Orphan
Acquired Orphan Blood Disease Market
Acquired Orphan Blood Disease Market to reach over USD 18.93 billion by the year 2031 - Exclusive Report by InsightAce Analytic
According to a new report by InsightAce Analytic, the "Acquired Orphan Blood Disease Market" in terms of revenue was estimated to be worth $8.65 billion in 2023 and is poised to reach $18.93 billion by 2031, growing at a CAGR of 10.47% from 2024 to 2031.
Get Free Access to…
Orphan Drugs Market Size to Hit $3199.3 Billion by 2028 | Orphan Drugs Industry …
Market Overview:
According to our experience research team, Orphan Drugs Market was valued at USD 112.36 Billion in 2021, and the global Orphan Drugs industry is projected to reach a value of USD 3199.3 Billion by 2028, at a CAGR of 7.4% during the forecast period 2022-2028
Vantage Market Research is a collection of market research studies on several industries, such as Chemicals, semiconductors & Electronics, Food & Beverages Technology, Energy &…
Orphan Drugs for Cancer Pipeline Analysis
A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group in recent years. It has been observed that majority of the orphan drugs in the clinical stages are for rare cancer disease drugs, and are in the late stages of the pipeline. Some of the drugs are being developed…
US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.…
Europe Orphan Drugs Pipeline Analysis
“Europe Orphan Drugs Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drug…
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the…
